• News & Resources

    News & Resources

    Learn More

  • Our Pipeline

    OUR PIPELINE

    A series of biosimilar drugs are currently under advanced clinical and nonclinical development stages. Based on the technology and capabilities established from the successful development of these biosimilars, the next tier of biosimilars and new antibody therapeutics are under development.

    Learn More

  • Our Technology

    OUR TECHNOLOGY

    Prestige Biopharma facilitates pharmaceutical R&D activities through well-equipped multidisciplinary infrastructure ranging from discovery through nonclinical and clinical development.

    Learn More


LATEST HAPPENINGS

IMG_9840 (1)

Prestige Biopharma had changed Stock name

from 'PBPharma' to 'PRESTIGE BIOPHARMA'(950210) as of March 2, 2021.

standardize our stock name with Prestige Biologics Co., Ltd. scheduled to be listed on KOSDAQ next month.

 

Officially announced on February 24, 2021 that our stock name will be changed from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’ as of March 2, 2021.

This change aims “to standardize our stock name with Prestige Biologics Co., Ltd. scheduled to be listed on KOSDAQ next month and provide a clear understanding of each company’s business areas”

 

About Prestige Biopharma

Prestige Biopharma (PB PHARMA) is a Singapore-based biopharmaceutical company focusing on the development of biosimilars and new antibody therapeutics.

Its lead program, HD201 trastuzumab biosimilar, has been filed with the EMA in 2019 and will also be filed with the USFDA in 2021.

Prestige BioPharma's next products in line include a Bevacizumab biosimilar (HD204) in Phase III,

an Adalimumab biosimilar (PBP1502) IND-ready for Phase I and an innovative anti-PAUF mAb (PBP 1510) for the treatment of pancreatic cancer also

IND-ready for Phase I/IIa. Manufacturing facilities for global commercial supply are located in Osong, South Korea.